Modality
Small Molecule
MOA
FGFRi
Target
FLT3
Pathway
Tau
FSGSBladder CaRSV
Development Pipeline
Preclinical
~Jul 2022
→ ~Oct 2023
Phase 1
~Jan 2024
→ ~Apr 2025
Phase 2
Jul 2025
→ Jan 2029
Phase 2Current
NCT07937433
977 pts·Bladder Ca
2025-07→2029-01·Active
977 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-052.8y awayPh2 Data· Bladder Ca
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2
Active
Catalysts
Ph2 Data
2029-01-05 · 2.8y away
Bladder Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07937433 | Phase 2 | Bladder Ca | Active | 977 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 | |
| RAR-440 | Ultragenyx | Phase 2 | FLT3 |